Cefotaxime

證據等級: L5

預測適應症: 10 個

Cefotaxime: From Bacterial Infections to Pneumococcal Meningitis

One-Sentence Summary

Cefotaxime is a third-generation cephalosporin antibiotic with established global use for serious bacterial infections, including central nervous system infections. Among the ten indications predicted by the TxGNN model, Pneumococcal Meningitis (TxGNN rank 8) is the only actionable candidate — ranked first by evidence quality — with 1 completed Phase 4 clinical trial and 20 publications, including multiple international treatment guidelines, collectively supporting an Evidence Level L1 classification. The top TxGNN-scored predictions (ranks 1–7, e.g., polyclonal hyperviscosity syndrome, congenital analbuminemia) all carry zero supporting evidence and a "Hold" recommendation; this report therefore focuses on the clinically meaningful finding.

Quick Overview

Item	Content
Original Indication	Serious bacterial infections (formal dataset entry unavailable; pharmacologically well-established)
Predicted New Indication	Pneumococcal Meningitis
TxGNN Prediction Score	96.73% (overall rank 8 by score; rank 1 by evidence strength)
Evidence Level	L1
Singapore Market Status	Not marketed (0 HSA registrations on record)
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Cefotaxime exerts its bactericidal effect by binding to penicillin-binding proteins PBP1A and PBP3, thereby inhibiting bacterial cell wall synthesis and causing cell lysis. This mechanism is directly applicable to Streptococcus pneumoniae, the causative organism in pneumococcal meningitis, against which cefotaxime demonstrates high in vitro potency (MIC90 typically ≤ 0.5 μg/mL). While formal MOA data was not retrievable from the DrugBank entry in this dataset, the mechanism is confirmed by the pharmacokinetic and pharmacodynamic evidence cited in the literature below.

A critical pharmacokinetic feature that makes cefotaxime particularly suited for CNS infections is its ability to cross the blood-brain barrier under conditions of meningeal inflammation. Cerebrospinal fluid (CSF) penetration reaches 10–20% of serum levels, sufficient to achieve and sustain bactericidal concentrations against susceptible pneumococci — a finding validated in a multicentre retrospective study of adult patients receiving high-dose cefotaxime for confirmed S. pneumoniae meningitis (PMID 34120184). This distinguishes cefotaxime from many antibiotics that fail to reach therapeutic CNS concentrations.

The connection between bacterial meningitis (cefotaxime's established domain) and pneumococcal meningitis specifically is direct and mechanistically unambiguous: S. pneumoniae remains the most common bacterial cause of meningitis in children beyond the neonatal period and in adults. National and international treatment guidelines from the United States (PMID 12182395), France (PMID 37741342), and other jurisdictions explicitly list cefotaxime or ceftriaxone as the empiric first-line backbone for bacterial meningitis, with or without vancomycin depending on local resistance patterns. The absence of Singapore HSA marketing authorisation represents a regulatory gap, not a gap in clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01540838	Phase 4	Completed	375	RCT conducted at Hospital Pediátrico David Bernardino, Angola. Tested whether slow continuous β-lactam (cefotaxime) infusion combined with high-dose oral paracetamol over the first 4 days reduces mortality in childhood bacterial meningitis, including pneumococcal meningitis, compared to traditional bolus dosing four times daily. Directly evaluates cefotaxime dosing optimisation in pneumococcal meningitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36326246	2022	Real-World Cohort	Antimicrobial Agents and Chemotherapy	40-year cohort (1977–2018) on treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis; defines cefotaxime MIC breakpoints per EUCAST and documents real-world therapy patterns
37741342	2023	Review / Guideline	Infectious Diseases Now	French national paediatric meningitis guideline; confirms that conjugate vaccination has eliminated most beta-lactam-resistant strains; cefotaxime/ceftriaxone remain standard of care for empiric treatment
12182395	2002	Review / Guideline	Pediatric Infectious Disease Journal	U.S. management guideline for pneumococcal meningitis; recommends cefotaxime or ceftriaxone + vancomycin as empiric therapy for all infants and children; discusses optimisation for strains with elevated MICs
34120184	2021	Multicentre Retrospective	Journal of Antimicrobial Chemotherapy	First multicentre study to describe CSF cefotaxime concentrations in adult pneumococcal meningitis patients receiving high-dose regimens; validates 10–20% CSF penetration as sufficient for bactericidal activity
4055060	1985	Clinical Study	Infection	46 consecutive patients (ages 1–79 years) with pneumococcal meningitis treated with cefotaxime monotherapy 200 mg/kg/day for 12–27 days; all isolates susceptible; established proof-of-concept clinical efficacy
19047432	2008	Review	Pediatrics in Review	Paediatric meningitis overview; empiric therapy in non-neonates is parenteral vancomycin + cefotaxime or ceftriaxone; reviews clinical presentation and outcome prediction
38558854	2024	Multicentre Cohort	Frontiers in Cellular and Infection Microbiology	Multicentre epidemiology of paediatric pneumococcal meningitis in China (2019–2020); reports drug sensitivity patterns of S. pneumoniae isolates relevant to Asian clinical settings
41342594	2025	Cohort Study	Revista Española de Quimioterapia	Tertiary hospital cohort; analyses serotype distribution, vaccination status, and clinical outcomes; identifies serotypes with highest invasive potential in the post-conjugate-vaccine era
16216469	2005	Comparative Study	International Journal of Antimicrobial Agents	Head-to-head comparison of CSF penetration and antimicrobial efficacy of cefotaxime (50 mg/kg q6h) vs ceftriaxone (100 mg/kg once daily) in paediatric bacterial meningitis caused by S. pneumoniae, H. influenzae, and N. meningitidis
33774218	2021	In Vitro Study	Journal of Global Antimicrobial Resistance	Evaluated daptomycin combinations with cefotaxime, amoxicillin, and rifampicin against major meningitis pathogens; cefotaxime used as the clinical reference standard, confirming its benchmark status

Singapore Market Information

Cefotaxime is not currently recorded as holding any HSA marketing authorisation in Singapore (0 licences on record in this dataset).

Important note: The absence of Singapore registration is clinically surprising given cefotaxime's worldwide guideline-endorsed status for bacterial meningitis. This finding likely reflects either a genuine market access gap (ceftriaxone may have displaced cefotaxime in this market) or an incomplete data capture. Current HSA registration status should be verified directly at HSA PRISM before drawing regulatory conclusions.

Safety Considerations

Formal product-specific safety data (HSA-approved warnings, contraindications, and drug interaction profiles) were not available in this dataset.

Please refer to the approved package insert (SmPC or local equivalent) for comprehensive safety information.

General class considerations applicable to cephalosporins:

Hypersensitivity: Anaphylaxis and other allergic reactions can occur; cross-reactivity with penicillins is estimated at 1–2%
GI effects: Clostridioides difficile-associated diarrhoea with prolonged use
Haematological: Rare drug-induced immune haemolytic anaemia (a case involving cefotaxime-sulbactam in a newborn with ABO incompatibility was identified in the literature, PMID 35003054 — relevant for neonatal use)
Renal: Generally low nephrotoxicity compared to aminoglycosides; dose adjustment required in severe renal impairment

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Pneumococcal meningitis is an L1-evidence indication for cefotaxime, endorsed by multiple international treatment guidelines and supported by validated CSF pharmacokinetics and decades of clinical use; the barrier to deployment is regulatory (no Singapore HSA registration on record), not clinical.

To proceed, the following is needed:

Verify HSA registration status — confirm whether cefotaxime is genuinely unregistered in Singapore or whether the dataset is incomplete; if unregistered, assess whether ceftriaxone (a closely related agent) is already registered and covers the same clinical need
Obtain the full package insert — required for Singapore-specific prescribing information including approved dosing, renal dose adjustments, and contraindications
Confirm local resistance surveillance data — review HSA or National Centre for Infectious Diseases (NCID) antibiogram data on S. pneumoniae cephalosporin susceptibility in Singapore to establish whether empiric cefotaxime remains appropriate without mandatory vancomycin co-administration
Establish the regulatory pathway — if product registration is required, evaluate HSA's abridged evaluation route (referencing established international approvals) or consider whether existing ceftriaxone registration already satisfies the clinical need
Safety review for vulnerable populations — given the neonatal safety signal identified (PMID 35003054), document risk-mitigation measures for paediatric use before finalising the clinical protocol
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.